12.35
Precedente Chiudi:
$12.46
Aprire:
$12.65
Volume 24 ore:
131.62K
Relative Volume:
0.98
Capitalizzazione di mercato:
$148.84M
Reddito:
-
Utile/perdita netta:
$-81.17M
Rapporto P/E:
-1.2186
EPS:
-10.1344
Flusso di cassa netto:
$-82.84M
1 W Prestazione:
-8.79%
1M Prestazione:
-23.67%
6M Prestazione:
-71.72%
1 anno Prestazione:
-65.59%
Korro Bio Inc Stock (KRRO) Company Profile
Nome
Korro Bio Inc
Settore
Industria
Telefono
617-468-1999
Indirizzo
60 FIRST STREET, CAMBRIDGE
Confronta KRRO con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
KRRO
Korro Bio Inc
|
12.35 | 148.84M | 0 | -81.17M | -82.84M | -10.13 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
2025-04-16 | Iniziato | Chardan Capital Markets | Buy |
2025-01-10 | Iniziato | Oppenheimer | Outperform |
2024-10-21 | Iniziato | Raymond James | Strong Buy |
2024-08-14 | Iniziato | William Blair | Outperform |
2024-03-28 | Reiterato | H.C. Wainwright | Buy |
2024-02-27 | Iniziato | BMO Capital Markets | Outperform |
2023-12-04 | Iniziato | H.C. Wainwright | Buy |
2023-11-29 | Iniziato | RBC Capital Mkts | Outperform |
2023-11-10 | Iniziato | Piper Sandler | Overweight |
2023-02-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
2023-02-13 | Downgrade | Cowen | Outperform → Market Perform |
2021-09-22 | Downgrade | Goldman | Buy → Neutral |
2021-01-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
2020-12-22 | Iniziato | B. Riley Securities | Buy |
2020-07-14 | Iniziato | Oppenheimer | Outperform |
2020-05-18 | Downgrade | JP Morgan | Overweight → Neutral |
2019-10-28 | Iniziato | Cowen | Outperform |
2019-10-28 | Iniziato | Goldman | Buy |
2019-10-28 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Korro Bio Inc Borsa (KRRO) Ultime notizie
Korro Bio, Inc. (NASDAQ:KRRO) Shares Acquired by California State Teachers Retirement System - Defense World
Cantor Fitzgerald Estimates Korro Bio FY2026 Earnings - Defense World
Wellington Management Group LLP Raises Stock Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Nuveen Asset Management LLC Purchases 17,131 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Jane Street Group LLC Makes New Investment in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Deutsche Bank AG Buys 935 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Buy” from Analysts - Defense World
KRRO stock touches 52-week low at $11.06 amid sharp annual decline By Investing.com - Investing.com South Africa
KRRO stock touches 52-week low at $11.06 amid sharp annual decline - Investing.com Nigeria
Korro Bio, Inc. (NASDAQ:KRRO) Shares Purchased by BNP Paribas Financial Markets - Defense World
Korro Bio’s SWOT analysis: RNA editing pioneer’s stock faces pivotal year By Investing.com - Investing.com South Africa
Korro Bio’s SWOT analysis: RNA editing pioneer’s stock faces pivotal year - Investing.com India
Korro Bio, Inc. (NASDAQ:KRRO) Stock Position Boosted by Northern Trust Corp - Defense World
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Brokers Offer Predictions for Korro Bio FY2025 Earnings - Defense World
Balyasny Asset Management L.P. Makes New Investment in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro to Participate in Upcoming Investor Conferences - The Manila Times
Korro Bio Leadership Takes Stage at Three Major Healthcare Conferences: RBC, Jefferies, and Goldman Sachs - Stock Titan
Korro Bio (KRRO) Rating and Price Target Maintained by Chardan C - GuruFocus
Oppenheimer Adjusts Price Target for Korro Bio (KRRO) Amid Secto - GuruFocus
Oppenheimer Lowers Price Target for Korro Bio (KRRO) But Maintai - GuruFocus
Oppenheimer Lowers Price Target for Korro Bio (KRRO) But Maintains Rating | KRRO Stock News - GuruFocus
Oppenheimer Adjusts Korro Bio Price Target to $90 From $155, Maintains Outperform Rating - marketscreener.com
Korro Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Korro Bio FY2025 EPS Estimate Raised by Cantor Fitzgerald - Defense World
Q2 Earnings Estimate for Korro Bio Issued By William Blair - Defense World
Q2 Earnings Forecast for Korro Bio Issued By HC Wainwright - Defense World
HC Wainwright Cuts Korro Bio (NASDAQ:KRRO) Price Target to $100.00 - Defense World
HC Wainwright Comments on Korro Bio FY2026 Earnings - Defense World
Wells Fargo & Company MN Raises Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
10,384 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Purchased by Barclays PLC - Defense World
10,347 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Acquired by Raymond James Financial Inc. - Defense World
Korro Bio (KRRO) Price Target Cut Amid Strategic Adjustments | K - GuruFocus
Korro Bio price target lowered to $53 from $130 at H.C. Wainwright - Yahoo Finance
Korro Bio Reports Q1 2025 Financial Results - TipRanks
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of “Buy” by Analysts - Defense World
Korro Bio stock price target lowered to $100 at H.C. Wainwright By Investing.com - Investing.com South Africa
Korro Bio stock price target lowered to $100 at H.C. Wainwright - Investing.com Nigeria
4 more biotechs cut staff amid market tumult - BioPharma Dive
ALX Oncology won’t seek approval for CD47 drug in gastric cancer; Korro Bio’s layoffs - Endpoints News
Korro lays off 20% of staff to fund genetic med trials, Novo Nordisk partnership - Fierce Biotech
Korro Bio (KRRO) Analyst Rating Update: Price Target Lowered | K - GuruFocus
Korro Bio (KRRO) Price Target Reduced, Buy Rating Maintained | K - GuruFocus
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Korro (KRRO) Surpasses Q1 Revenue Expectations Amid Promising Cl - GuruFocus
Korro Bio Announces Strategic Workforce Reduction Plan - TipRanks
Korro Bio, Inc. SEC 10-Q Report - TradingView
Korro Bio, Inc. Reports Q1 2025 Financial Results and Updates on KRRO-110 Development for Alpha-1 Antitrypsin Deficiency - Nasdaq
JPMorgan Chase & Co. Sells 9,537 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Legal & General Group Plc Raises Stock Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Analysts Offer Predictions for Korro Bio FY2025 Earnings - Defense World
Korro Bio Inc Azioni (KRRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Korro Bio Inc Azioni (KRRO) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Agarwal Vineet | Chief Financial Officer |
Nov 11 '24 |
Sale |
70.00 |
800 |
56,000 |
0 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):